Why InfoBionic?

InfoBionic is a digital health company focused on creating superior patient monitoring solutions for chronic disease management with an initial market focus on cardiac arrhythmias. InfoBionic has 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for MoMe® Kardia, a wireless, remote monitoring system designed to aid physicians in their diagnosis of cardiac arrhythmia. MoMe® Kardia is comprised of a wearable MoMe Kardia device that can acquire, store and send full disclosure ECG and other related data. This data is continuously transmitted to the cloud-based MoMe Software System using MoMe Device Communication Protocol. The proprietary software analyzes the data, which can be flagged for physician review on a Web-based physician portal.

Market Opportunity

The global addressable market for monitoring cardiac arrhythmia and related events is estimated to be approximately $3 billion worldwide, including $1 billion in the U.S.

(Visited 3,259 times, 1 visits today)

Company Milestones

  • InfoBionic receives CE Mark for its MoMe® System for cardiac arrhythmia monitoring
  • InfoBionic appoints Steven R. Wasserman as CFO
  • InfoBionic raises $8M in Series B-1 financing led by Safeguard Scientifics
  • InfoBionic receives FDA 510(k) clearance for MoMe® Kardia
  • InfoBionic Names Industry Veteran Stuart Long Chief Executive Officer

Making a vital change in arrhythmia detection and monitoring efficiency.